Clinical Trials Logo

Clinical Trial Summary

Primary Objectives:

1. To explore the experience of chronic graft-versus-host disease (cGVHD) following allogeneic blood or marrow transplantation from the perspective of the patient and the patient's primary family caregiver.

2. To develop and validate an instrument to measure the severity of multiple symptoms and the impact of these symptoms on daily functioning in patients who have cGVHD.

Secondary Objectives:

1. To develop a detailed description of the experience of having cGVHD.

2. To develop a detailed description of the symptom experience of cGVHD to allow for development of a symptoms instrument for cGVHD.

3. To assess the understanding of questions to measure the symptoms of cGVHD in patients with various levels of education.

4. To develop a detailed description of caring for a patient with cGVHD.


Clinical Trial Description

For Patient:

If you agree to take part in this study, you will be asked to take part in 1 interview. During the interview, you will be asked to describe what it has been like for you to have chronic GVHD. In addition, if you agree to take part in this study, your family caregiver, if you have one, will be approached to take part in the study.

For Caregiver:

If you agree to take part in this study, you will be asked to take part in 1 interview. During the interview, you will be asked to describe what it has been like for you to help care for a family member with chronic GVHD.

Both Parties:

The interview face-to-face will take place while you are at M. D. Anderson receiving care. You will be interviewed alone and the information gathered during the interview will be strictly confidential. The interview will take about 30 minutes and will be tape recorded. The audiotape of the interview will be kept in a locked cabinet in the office of the study chairperson Dr. Loretta Williams. If other study personnel need the tape for analysis, they must obtain the tape directly from Dr. Williams. They may keep the tape only while they are listening to it and must return it immediately to Dr. Williams. Identification labels on the tape will only contain your study number and will not contain your name, medical record number, or other identifying information. When all analysis for the study has been completed and reported, the audiotape will be destroyed.

After the interview, you will be asked to answer a face-to-face questionnaire. This questionnaire will ask descriptive personal information (age, marital status, etc.). Answering these questions should take about 5 minutes.

Your participation on this study ends after you complete the interview and questionnaire.

This is an investigational study. About 20 patients and 20 caregivers will take part in this study. All will be enrolled at M. D. Anderson.

For Patient - Phase III:

If you agree to take part in this study, you will be asked to complete 1 questionnaire. The questionnaire will have questions asking you to rate how severe your current symptoms are and how much these symptoms disrupt your daily activities. You will be asked to complete this questionnaire during your clinic visit. The questionnaire will take no more than 10 minutes to complete.

If you have chronic graft-versus-host disease, you will be asked to complete a second questionnaire about your opinion of the symptom questionnaire (the first questionnaire). For example, you will be asked if the symptom questionnaire was easy to understand and to complete. Learning your opinion about this questionnaire will help researchers learn what important questions may be missing from the questionnaire. The questionnaire will take no more than 10 minutes to complete.

If you have chronic graft-versus-host disease, you will also be given questions asking you to rate the overall quality of your life and your ability to function. These ratings should take no more than 2 minutes to complete.

Finally, you will be asked to answer a questionnaire. This questionnaire will ask descriptive personal information (such as age and marital status). Answering these questions should take about 5 minutes.

If you have chronic GVHD, you may be asked to fill out the questionnaire rating your symptoms 1 more time, about 3 days after you completed it the first time. You will return this second questionnaire to the research staff in a pre-addressed, stamped envelope given to you by the research staff. If you are asked to complete the questionnaire this second time, the research staff will also ask for your telephone number so that they may contact you and remind you to complete the questionnaire.

Identification labels on all study questionnaires and forms will only contain your study number and will not contain your name, medical record number, or other identifying information. All study materials will be kept in a locked cabinet at all times. When all analysis for the study has been completed and reported, the questionnaires will be destroyed.

The study ends when you have completed the questionnaires, rating scales, and interview in the clinic, or when you have completed and returned the second questionnaire 3 days after your clinic visit.

This is an investigational study. Up to 192 patients will take part in this study. 147 will be enrolled at M. D. Anderson and 45 will be enrolled at Roswell Park Cancer Institute. ;


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00353106
Study type Observational
Source M.D. Anderson Cancer Center
Contact
Status Completed
Phase N/A
Start date February 2006
Completion date January 2010

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Not yet recruiting NCT00749164 - Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment Phase 1/Phase 2
Completed NCT00993343 - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Phase 3
Completed NCT00360685 - Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX N/A
Active, not recruiting NCT04503616 - Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention Phase 1/Phase 2
Terminated NCT02080195 - Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Completed NCT02193880 - Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) N/A
Completed NCT02942173 - CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT Phase 2/Phase 3
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT01941394 - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Phase 2
Completed NCT00141713 - The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease Phase 2
Recruiting NCT01991301 - Carfilzomib for the Prevention of Graft Versus Host Disease Phase 1
Completed NCT00408928 - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease Phase 2
Completed NCT01633229 - Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications Phase 1
Completed NCT05856058 - To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability Phase 1
Completed NCT02342613 - Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Phase 1
Recruiting NCT06423131 - Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT N/A
Completed NCT02144025 - Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT Phase 2
Completed NCT01369914 - The Natural History of Graft-Versus-Host Disease in the Eyes
Completed NCT00806728 - Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease Phase 1